MDPI - Publisher of Open Access Journals

15 pages, 1381 KiB

Open AccessArticle

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

by Anu Partanen, Anders Waage, Valdas Peceliunas, Fredrik Schjesvold, Pekka Anttila, Marjaana Säily, Katarina Uttervall, Mervi Putkonen, Kristina Carlson, Einar Haukas, Marja Sankelo, Damian Szatkowski, Markus Hansson, Anu Marttila, Ronald Svensson, Per Axelsson, Birgitta Lauri, Maija Mikkola, Conny Karlsson, Johanna Abelsson, Erik Ahlstrand, Anu Sikiö, Monika Klimkowska, Reda Matuzeviciene, Mona Hoysaeter Fenstad, Sorella Ilveskero, Tarja-Terttu Pelliniemi, Hareth Nahi and Raija Silvennoinen Show full author list Hide full author list

Cancers 2024, 16(5), 1024; https://doi.org/10.3390/cancers16051024 - 29 Feb 2024

Cited by 2 | Viewed by 2963

Abstract

Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of four cycles of ixazomib–lenalidomide–dexamethasone (IRD) induction plus autologous stem cell transplantation followed by IRD consolidation and cytogenetic risk-based maintenance therapy with lenalidomide + ixazomib (IR) for HR patients and lenalidomide (R) alone for NHR patients. The main endpoint of the study was undetectable minimal residual disease (MRD) with sensitivity of <10⁻⁵ by flow cytometry at any time, and other endpoints were progression-free survival (PFS) and overall survival (OS). We present the preplanned analysis after the last patient has been two years on maintenance. At any time during protocol treatment, 28% (34/120) had MRD < 10⁻⁵ at least once. At two years on maintenance, 66% of the patients in the HR group and 76% in the NHR group were progression-free (p = 0.395) and 36% (43/120) were CR or better, of which 42% (18/43) had undetectable flow MRD <10⁻⁵. Altogether 95% of the patients with sustained MRD <10⁻⁵, 82% of the patients who turned MRD-positive, and 61% of those with positive MRD had no disease progression at two years on maintenance (p < 0.001). To conclude, prolonged maintenance with all-oral ixazomib plus lenalidomide might improve PFS in HR patients. Full article

(This article belongs to the Collection Advances in Multiple Myeloma Research and Treatment)

► Show Figures

Figure 1

12 pages, 1021 KiB

Open AccessReview

New Targets for PET Imaging of Myeloma

by Mona-Elisabeth Revheim, Caroline Stokke, Jakob Nordberg Nørgaard, Hilde Feiring Phillips, Alexander Gul Sherwani, Fredrik Schjesvold and James P. Connelly

Hemato 2021, 2(4), 727-738; https://doi.org/10.3390/hemato2040049 - 2 Dec 2021

Cited by 3 | Viewed by 6537

Abstract

Recent advances in the treatment of multiple myeloma (MM) have increased the need for accurate diagnosis and detection of minimal residual disease (MRD), disease characterization and localization, and response evaluation and prognostication. Positron emission tomography (PET)/computed tomography (CT) imaging combines molecular and morphological information and has been shown to be especially valuable in this disease. The most frequently used PET tracer in MM is the glucose analog 18F-fluorodeoxyglucose ([¹⁸F]FDG). [¹⁸F]FDG PET/CT has a sensitivity for detection of MM between 80% to 100% and is currently the main imaging modality for assessing treatment response and for determining MRD. However, 18F-FDG PET/CT has some limitations, and imaging with alternative tracers that may overcome these constraints should be further explored. This article discusses new targets for PET/CT imaging in the assessment of MM. Full article

(This article belongs to the Special Issue Current and Upcoming Diagnostics and Prognostics in Multiple Myeloma)

► Show Figures

Figure 1

20 pages, 519 KiB

Open AccessReview

Current and Novel Alkylators in Multiple Myeloma

by Fredrik Schjesvold and Albert Oriol

Cancers 2021, 13(10), 2465; https://doi.org/10.3390/cancers13102465 - 18 May 2021

Cited by 13 | Viewed by 5452

Abstract

A large number of novel treatments for myeloma have been developed and approved; however, alkylating drugs continue to be part of standard regimens. Additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors’ knowledge of the field, to review the history, current use and novel concepts around the traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted treatment and personalized medicine, alkylating drugs continue to be part of the standard-of-care in myeloma, and new alkylators are coming to the market. Full article

(This article belongs to the Special Issue Novel Therapeutic Strategies in Multiple Myeloma (MM))

► Show Figures

Figure 1

10 pages, 272 KiB

Open AccessCommentary

Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2

by Jill Corre, Michele Sabbah, Fredrik Schjesvold, Amer M. Zeidan, Francesco Buccisano, David Sallman, Mario Mazzucato, Leigh A. Madden, Maurizio Martini, Eric Van Breda, Riccardo Dolcetti, Alessandro Busca, Gordon Cook, Francesco Onida, Annibale Versari, Jean-Jacques Kiladjian, Roland B. Walter, Laurent Garderet, Marie Robin and Alberto Signore

Hemato 2021, 2(1), 79-88; https://doi.org/10.3390/hemato2010004 - 9 Feb 2021

Cited by 1 | Viewed by 3646

Abstract

Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of commentary article which is published on a biannual basis by the editorial board of the journal Hemato [...] Full article

(This article belongs to the Collection Exclusive Papers of the Editorial Board Members (EBMs) of Hemato)

13 pages, 979 KiB

Open AccessReview

The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study

by Anne-Marie Rasmussen, Frida Bugge Askeland and Fredrik Schjesvold

Hemato 2020, 1(2), 36-48; https://doi.org/10.3390/hemato1020008 - 24 Sep 2020

Cited by 3 | Viewed by 4799

Abstract

The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment. Full article

(This article belongs to the Collection Exclusive Papers of the Editorial Board Members (EBMs) of Hemato)

► Show Figures

Figure 1

13 pages, 298 KiB

Open AccessEditorial

Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1

by Jude Fitzgibbon, Sophie Park, Gordon Cook, Bruno Paiva, Annunziata Gloghini, Eric Van Breda, Fabiana Busti, Laurent Garderet, Ricardo Dolcetti, Marie Robin, Rodrigo Martino, Alessandro Busca, Michèle Sabbah, Salvatore De Rosa, Maurizio Martini, Francesco Onida, Pierre Aucouturier, Fredrik Schjesvold, Stéphane Minvielle, Mario Mazzucato, Carolina Terragna, Michel Delforge, Claire Harrison and Antonino Carbone Show full author list Hide full author list

Hemato 2020, 1(1), 10-22; https://doi.org/10.3390/bloods1010005 - 1 Jul 2020

Viewed by 5658

Abstract

Recent Advancements in Hematology: Knowledge, Methods and Dissemination is a series of editorials which is published on a biannual basis by the editorial board of the journal Bloods [...] Full article

(This article belongs to the Collection Exclusive Papers of the Editorial Board Members (EBMs) of Hemato)

Search Results (6)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI

Saved Queries

Search Filter Reset All

Years

Feature Papers

Subjects

Journals

Article Types

Countries / Regions

Search Results (6)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI